Analytical Data
-
Gene name
CD14
- Application
-
Alternative Names
CD14；Monocyte differentiation antigen CD14
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P08571
-
Expression Region
20-352aa
-
AA Sequence
TTPEPCELDDEDFRCVCNFSEPQPDWSEAFQCVSAVEVEIHAGGLNLEPF LKRVDADADPRQYADTVKALRVRRLTVGAAQVPAQLLVGALRVLAYSRLK ELTLEDLKITGTMPPLPLEATGLALSSLRLRNVSWATGRSWLAELQQWLK PGLKVLSIAQAHSPAFSCEQVRAFPALTSLDLSDNPGLGERGLMAALCPH KFPAIQNLALRNTGMETPTGVCAALAAAGVQPHSLDLSHNSLRATVNPSA PRCMWSSALNSLNLSFAGLEQVPKGLPAKLRVLDLSCNRLNRAPQPDELP EVDNLTLDGNPFLVPGTALPHEGSMNSGVVPAC
-
Molecular Weight
36 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD14 is a crucial glycoprotein primarily expressed on the surface of monocytes and macrophages, acting as a pattern recognition receptor that plays a significant role in the immune response. It binds to lipopolysaccharides (LPS) and other microbial components, facilitating the recognition of pathogens and the subsequent activation of inflammatory pathways. Given its central role in mediating innate immunity and inflammation, CD14 has garnered attention in various research fields, including infectious diseases, autoimmune disorders, and cancer. The production of recombinant CD14 protein enables the exploration of its biological functions, potential therapeutic applications, and provides valuable insights into its role in disease mechanisms. Additionally, recombinant CD14 can be used for developing diagnostic tools and novel therapies targeting infectious agents or modulating immune responses. The study of this protein holds promise for elucidating the complexities of immune interactions and enhancing our understanding of immunological diseases. As researchers continue to investigate recombinant CD14, its implications in clinical settings, such as sepsis and chronic inflammatory conditions, are particularly noteworthy, potentially leading to innovative strategies for managing these disorders.
